8-K: Waters Corp Reports Strong 2025, Transforms with BD Biosciences Acquisition

Waters Corporation announced robust fourth quarter and full-year 2025 financial results, highlighted by double-digit non-GAAP EPS growth and the strategic acquisition of BD Biosciences and Diagnostic Solutions.

Summary

• Fourth quarter 2025 sales reached $932 million, an increase of 7% as reported and 6% in constant currency, landing at the high-end of guidance.
• Full-year 2025 sales were $3,165 million, growing 7% as reported and in constant currency.
• GAAP diluted earnings per share (EPS) for Q4 2025 was $3.77, compared to $3.88 for Q4 2024.
• Non-GAAP EPS for Q4 2025 grew 10% to $4.53, compared to $4.10 for Q4 2024.
• Full-year 2025 GAAP EPS was $10.76, compared to $10.71 for fiscal year 2024.
• Full-year 2025 non-GAAP EPS increased 11% to $13.13, compared to $11.86 for fiscal year 2024.
• Growth was led by high single-digit constant currency growth in Pharma (7% in Q4, 9% in FY) and Industrial (8% in Q4, 6% in FY) end-markets.
• Chemistry segment grew 12% in constant currency for both Q4 and Full-Year 2025, driven by new bioseparations products.
• The acquisition of BD Biosciences and Diagnostic Solutions closed on February 9, 2026, marking a transformative step for Waters.
• Full-year 2026 guidance projects total company revenue between $6.405 billion and $6.455 billion, with non-GAAP EPS in the range of $14.30 to $14.50, representing 8.9% to 10.4% growth.
• First quarter 2026 guidance anticipates total company revenue between $1.198 billion and $1.211 billion, with non-GAAP EPS in the range of $2.25 to $2.35.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, marked by solid operational performance, double-digit non-GAAP EPS growth, and a transformative acquisition that significantly expands market reach and future growth potential, despite a slight GAAP EPS dip in Q4.

Positives

• Achieved high single-digit revenue growth and double-digit adjusted EPS growth for the full year 2025.
• Fourth quarter 2025 sales of $932 million landed at the high-end of reported sales growth guidance range.
• Strong constant currency growth in the Pharmaceutical (7% in Q4, 9% in FY) and Industrial (8% in Q4, 6% in FY) end-markets.
• Chemistry segment demonstrated robust growth of 12% in constant currency for both Q4 and Full-Year 2025, driven by significant customer demand for new bioseparations products.
• Recurring Revenue grew 8% in constant currency for Full-Year 2025, indicating a stable and growing revenue base.
• The strategic acquisition of BD Biosciences and Diagnostic Solutions is expected to be transformative, driving significant revenue and cost synergies.
• Full-year 2026 guidance projects an attractive 5.3% combined company sales growth at mid-point and non-GAAP EPS growth of 8.9% to 10.4%, including $0.10 cents of accretion from the acquisition.
• Cash and cash equivalents increased significantly to $587,831 thousand at December 31, 2025, from $325,355 thousand at December 31, 2024.

Negatives

• GAAP EPS for the fourth quarter of 2025 decreased to $3.77 from $3.88 in the fourth quarter of 2024.
• Sales into the Academic & Government market decreased 3% in constant currency in Q4 2025 and 1% in constant currency for Full-Year 2025.
• The TA (Thermal Analysis) operating segment experienced flat sales in Q4 2025 and a 1% decrease for Full-Year 2025 in constant currency.
• Instruments growth (3% constant currency in Q4) was partially offset by the TA segment's performance and the transition to a subscription model for Empower.
• First quarter 2026 non-GAAP EPS growth guidance is relatively modest, ranging from 0.0% to 4.4% year-over-year.

Risks

• Risks and uncertainties related to the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business.
• Potential for unexpected costs, charges, or expenses resulting from the acquisition.
• Difficulties and delays in achieving expected revenue and cost synergies related to the acquisition.
• Increased indebtedness of the Company as a result of the acquisition.
• Uncertainties regarding future financial and operational performance.
• Impact of future economic and market conditions, including expectations about market growth rates.
• Ability to respond and adapt to changing global dynamics, including potential impacts of tariffs and supply chain challenges.
• Ability to retain and attract customers in various geographies and market segments.
• Competitive positioning within the industry.
• Challenges related to projected costs, technological capabilities and plans, and objectives of management.

Future Outlook

Waters Corporation anticipates continued momentum into 2026, driven by strong execution of the multi-year instrument replacement cycle, pioneering innovation, and Waters-specific idiosyncratic growth drivers. The recent acquisition of BD Biosciences and Diagnostic Solutions is expected to be transformative, contributing approximately $3.000 billion to full-year 2026 reported revenue and $50 million in revenue synergies. Full-year 2026 total company revenue is projected to be between $6.405 billion and $6.455 billion, with non-GAAP EPS in the range of $14.30 to $14.50, representing 8.9% to 10.4% growth. First quarter 2026 guidance includes total company revenue of $1.198 billion to $1.211 billion and non-GAAP EPS of $2.25 to $2.35.

Management Comments

• "Our team delivered industry-leading results in 2025, achieving high single-digit revenue growth and double-digit adjusted EPS growth."
• "We expect this momentum to continue into 2026, driven by strong execution of the multi-year instrument replacement cycle, continued contribution from pioneering innovation, and our Waters-specific idiosyncratic growth drivers."
• "As we enter 2026, the addition of BD Biosciences and Diagnostic Solutions marks a transformative step forward for Waters."
• "Today, we will close the transaction and are launching commercial excellence initiatives tied to instrument replacement, e-commerce, and service attachment that will build momentum and drive the first phase of our stated revenue synergies."
• "Within the P&L, we also expect to make decisive progress towards realizing our stated cost synergies in the months ahead."
• "Our starting 2026 guidance calls for an attractive 5.3% combined company sales growth at mid-point, with opportunity for outperformance as the year progresses."

Industry Context

StockSavvy.ai notes that Waters Corporation's strategic acquisition of BD Biosciences and Diagnostic Solutions positions it for significant expansion in the life sciences sector, aligning with broader industry trends of consolidation and diversification into high-growth areas like bioseparations and diagnostics. The focus on instrument replacement cycles and e-commerce initiatives reflects a common strategy among analytical instrument providers to enhance recurring revenue streams and customer engagement in a competitive market.

Stakeholder Impact

• Shareholders: Potential for increased value through strategic acquisition, expected revenue and cost synergies, and projected EPS growth. Increased indebtedness from the acquisition could be a factor to monitor.
• Customers: Expanded product and service offerings through the BD Biosciences acquisition, potentially leading to more comprehensive solutions and enhanced support.
• Employees: Integration of BD Biosciences employees, potential for new roles and responsibilities, but also risks associated with restructuring and synergy realization.

Next Steps

• Continue momentum into 2026, driven by strong execution of the multi-year instrument replacement cycle, pioneering innovation, and Waters-specific idiosyncratic growth drivers.
• Launch commercial excellence initiatives tied to instrument replacement, e-commerce, and service attachment to build momentum and drive revenue synergies.
• Make decisive progress towards realizing stated cost synergies in the months ahead.
• Host a webcast of the fourth quarter 2025 financial results conference call on February 9, 2026, at 8:30 a.m. Eastern Time.

Key Dates

Recommendation

The company delivered strong financial results for 2025, particularly in non-GAAP EPS growth and sales at the high end of guidance. The strategic acquisition of BD Biosciences and Diagnostic Solutions is a transformative move, significantly expanding Waters' market presence and offering substantial revenue and cost synergy potential. The robust 2026 guidance, projecting significant revenue growth and continued double-digit non-GAAP EPS growth (including accretion from the acquisition), indicates a strong positive outlook. While there are integration risks, the strategic rationale and projected financial benefits make this a compelling investment opportunity.

Keywords

Analytical Instruments, Separations Technologies, Software, Life Sciences, Materials Sciences, Food Sciences, Environmental Sciences, Bioseparations, LC-MS, Empower, BD Biosciences, Diagnostic Solutions, Acquisition, Financial Results, EPS, Revenue, Constant Currency, Pharma, Industrial, Recurring Revenue